Navigation Links
Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
Date:4/21/2009

Conference Call and Webcast to Follow

THE WOODLANDS, Texas, April 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2009 financial results on Tuesday, April 28, 2009 before the financial markets open. Lexicon management will hold a conference call to discuss its clinical development progress and financial results for first quarter 2009 at 11:00 a.m. Eastern Time on April 28, 2009.

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international). The conference ID for all callers is 95206081. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through May 5, 2009.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Lexicon Appoints Judith Swain, M.D. to Board of Directors
4. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
5. Lexicon Pharmaceuticals to Present at Bio InvestorForum
6. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
7. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
8. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
9. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
10. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
11. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or ... pleased to announce that Biohaven has issued today the ... Connecticut (PRWEB) Dec 9, 2016 - Biohaven ... today that the U.S. Food and Drug Administration ("FDA") ... its drug candidate BHV-0223, an orally dissolving tablet being ...
(Date:12/8/2016)... PITTSBURGH , Dec. 8, 2016  The Board ... (PLSG), Western Pennsylvania,s only ... in leadership. In accordance with the succession plan developed ... several years, effective today, James (Jim) F. Jordan ... Executive Officer, succeeding John W. Manzetti , who ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... Lajollacooks4u, San ... a banner year for team building events, new program offerings and company expansion. ... expanded earlier this year to include groups of over 30 people. Ever since, Lajollacooks4u ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... platforms, the business of innovation is taking over sports. On Thursday, December 15th ... explore how technology is disrupting the playing field at a Smart Talk session. ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016   Neurotechnology , a provider ... technologies, today released FingerCell 3.0, a software ... that run on low-power, low-memory microcontrollers. FingerCell ... than 128KB of memory, enabling it to ... limited on-board resources, such as: mobile phones, ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
Breaking Biology News(10 mins):